Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 16510768.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In vitro and animal model data demonstrate that valproic acid (VPA) can ameliorate HIV-associated neurotoxicity. The authors conducted a pilot 10-week placebo-controlled study of VPA 250 mg twice daily in 22 HIV-infected individuals with (n = 16) and without (n = 6) cognitive impairment. VPA was safe and well tolerated, with trends toward improved neuropsychological performance and brain metabolism in the impaired subjects.
Medical subject headings
- AIDS Dementia Complex
- HIV Infections
- HIV-1
- Valproic Acid